On Wednesday, May 27, Zynerba (NASDAQ:ZYNE) reported positive data from its phase II trial testing its cannabinoid drug Zygel to treat pediatric and adolescent patients with autism spectrum disorder (ASD). The stock rose in Wednesday morning trading to $6.30 per […]